rs10050860 — ERAP1 D575N

ERAP1 D575N — A Secondary Dial in the Peptide-Trimming Machine

Your immune system runs a continuous quality-control operation inside every cell. Proteins are constantly degraded, and small fragments — peptides — are trimmed to the correct 8-10 amino acid length¹¹ trimmed to the correct 8-10 amino acid length
a precisely sized peptide is required for stable binding to MHC class I molecules on the cell surface; peptides that are too long or too short cannot bind and are discarded by ERAP1 (Endoplasmic Reticulum Aminopeptidase 1) before being loaded onto HLA class I display platforms. This curated peptide sample is then presented on the cell surface for inspection by patrolling CD8+ T cells — the checkpoint that determines whether a cell is "self" or dangerous.

The D575N variant changes a single amino acid in ERAP1's catalytic domain. This substitution does not knock out the enzyme, but it measurably alters trimming efficiency — and in individuals carrying the HLA-B27 antigen, those alterations compound into a meaningful shift in ankylosing spondylitis risk. D575N's effect is context-dependent: it acts synergistically with the more powerful K528R variant (rs30187) to define one of the most well-characterized ERAP1 risk haplotypes in human genetics.

The Mechanism

ERAP1's catalytic domain contains a zinc-active site that cleaves amino acids from the N-terminus of precursor peptides. Position 575 lies within this domain, and the Asp575 residue (C allele) engages in electrostatic interactions that influence the geometry of the active site. The D575N substitution — replacing the negatively charged aspartic acid with the neutral asparagine — subtly perturbs these interactions.

Biochemical characterization of naturally occurring ERAP1 variants shows that Asp575 confers modestly lower trimming activity compared to Asn575, but critically, the magnitude of this effect depends strongly on residue 528 (the K528R variant, rs30187). Functional epistasis studies²² Functional epistasis studies
Evnouchidou et al. 2014: combined effects of ankylosing spondylitis-associated ERAP1 polymorphisms outside the catalytic and peptide-binding sites on the processing of natural HLA-B27 ligands. J Biol Chem, 2014 established the activity hierarchy: Arg528/Asp575 < Lys528/Asp575 < Arg528/Asn575 < Lys528/Asn575. In this ordering, the D (Asp575, C allele at rs10050860) combination with K528 (the rs30187 risk allele) produces the highest enzymatic activity — paradoxically, the risk combination for AS.

This apparent paradox is explained by the nature of ERAP1's role in HLA-B27 biology. HLA-B27 is unusual among HLA class I alleles: it preferentially presents longer, arginine-terminated peptides. ERAP1 over-trimming of HLA-B27 ligands can generate a mis-edited peptide repertoire that triggers autoimmune T cell responses and/or drives HLA-B27 heavy chain misfolding and endoplasmic reticulum stress. Both high-activity and low-activity ERAP1 allotypes can create pathogenic peptide landscapes depending on the specific HLA alleles present.

The Evidence

ERAP1 haplotype and AS susceptibility. The foundational haplotype study by Evans et al. 2009³³ Evans et al. 2009
Association of a specific ERAP1/ARTS1 haplotype with disease susceptibility in ankylosing spondylitis. Arthritis Rheum, 2009 identified a three-SNP haplotype — rs27044/rs10050860/rs30187 coded as CCT — as strongly associated with increased AS risk (pooled OR=1.81, 95% CI 1.46-2.24, P=7×10⁻⁸ across three Canadian cohorts). The rs10050860 C allele (Asp575) is the risk allele in this haplotype. The complementary protective haplotype (rs27044/rs26618/rs30187-CTG, OR=0.77) confirmed the directionality.

Meta-analytic confirmation. A meta-analysis combining 8,530 AS cases and 12,449 controls found that the rs10050860 T allele (Asn575) was significantly protective against AS in European populations, with an OR=0.724 (95% CI 0.665-0.787, P<1×10⁻¹⁰)⁴⁴ OR=0.724 (95% CI 0.665-0.787, P<1×10⁻¹⁰)
Associations between ERAP1 polymorphisms and ankylosing spondylitis susceptibility: a meta-analysis. Arthritis Care Res, 2011. This protective effect is among the strongest individual ERAP1 SNP associations documented, second only to rs30187 in European-ancestry studies.

A PNAS 2017 analysis⁵⁵ PNAS 2017 analysis
ERAP1 association with AS is attributable to common genotypes rather than rare haplotype combinations confirmed that rs10050860 contributes to common genotype combinations that account for the bulk of the ERAP1-AS association, and that the effect is not driven by rare haplotypes. D575N (along with K528R) defines the most prevalent risk and protective ERAP1 genotype classes in the population.

Co-protective state with rs30187. When both rs10050860 T (Asn575) and rs30187 C (Lys528) are inherited together, the combined protective effect on AS risk is substantial. In HLA-B27-positive individuals, this double-protective state reduces AS risk approximately 3-4 fold⁶⁶ this double-protective state reduces AS risk approximately 3-4 fold
Evans et al. 2011: HLA-B27-positive individuals homozygous for protective ERAP1 alleles had substantially lower AS risk than those carrying risk alleles at either or both ERAP1 loci. Nat Genet, 2011. This co-protective effect is functionally grounded: inheriting low-activity alleles at both key positions (528 and 575) produces an ERAP1 enzyme whose trimming kinetics minimally disturb the HLA-B27 peptide repertoire.

Functional ranking. Proteomics-level studies of ERAP1 variant combinations showed that while K528R (rs30187) is the dominant contributor to HLA-B27 peptidome shaping, D575N amplifies the K528R effect and independently contributes to reduced trimming efficiency. Ranking studies⁷⁷ Ranking studies
Kochan et al. 2018, ranking the contribution of AS-associated ERAP1 polymorphisms to shaping the HLA-B27 peptidome noted that D575N's contribution to the HLA-B27 peptidome changes — while smaller than K528R's — is consistently directional and adds to the overall allotype effect.

Important caveat on independent effect. A subset of the rs10050860 signal may be attributable to strong linkage disequilibrium with a nearby splice-altering variant, rs7063, which influences ERAP1 protein levels rather than catalytic function. This does not invalidate the D575N finding — the functional studies above directly demonstrate biochemical effects — but it means the full AS association magnitude at this locus may reflect a combination of coding and regulatory mechanisms.

Practical Implications

Carrying the C allele at rs10050860 (Asp575) means your ERAP1 trimming activity at this position is at the population baseline or slightly higher. On its own, this does not cause disease. The clinical significance of this variant is nearly entirely contingent on your HLA-B27 status and on your rs30187 genotype.

If you carry HLA-B27, the C allele at rs10050860 (particularly if combined with the T allele at rs30187) represents the risk configuration — the ERAP1 allotype that most strongly shifts the HLA-B27 peptidome toward arthritogenic states. Early recognition of ankylosing spondylitis symptoms matters: the disease is effectively managed with NSAIDs and biologics when caught early, but causes irreversible spinal fusion when untreated for years.

If you are homozygous TT at rs10050860, your Asn575 ERAP1 contributes to reduced enzymatic activity. When combined with the CC genotype at rs30187 (Lys528), this double-protective state confers substantially reduced AS risk compared to the risk haplotype.

Interactions

rs10050860 × rs30187 (K528R): Same-gene functional epistasis. The effects of D575N and K528R are not additive — they interact. The activity hierarchy depends on the combination of residues at both positions. Asp575+Lys528 is higher-activity than either protective combination; Asn575+Arg528 is the lowest-activity, most protective allotype for AS. This interaction is the strongest rationale for analyzing both variants together in a compound action context.

rs10050860 × HLA-B27: Disease-determining epistasis. Like all ERAP1 coding variants, D575N's contribution to AS risk operates exclusively through its interaction with HLA-B27. In HLA-B27-negative individuals, the C vs T genotype at rs10050860 has no meaningful AS association. The clinical weight of this variant should be interpreted entirely in the context of HLA-B27 status.

rs10050860 in the ERAP1 haplotype system. ERAP1 has been catalogued into 10+ naturally occurring haplotypes (Hap1-Hap10) defined by combinations of variants including rs30187, rs10050860, rs27044, rs27524, and others. The predominant risk haplotype (MKDRQ: Met349-Lys528-Asp575-Arg725-Gln730) is defined partly by D (Asp575, rs10050860 C allele). The predominant protective haplotype (VRNQE) carries N575 (rs10050860 T allele). Haplotype-level analysis provides a more complete picture than individual SNP analysis for ERAP1 allotype classification.